Anti-Tumor Efficacy of In Situ Vaccination Using Bacterial Outer Membrane Vesicles
In situ vaccination (ISV) is a promising cancer immunotherapy strategy that consists of the intratumoral administration of immunostimulatory molecules (adjuvants). The rationale is that tumor antigens are abundant at the tumor site, and therefore, to elicit an effective anti-tumor immune response, a...
| Main Authors: | , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2023-06-01
|
| Series: | Cancers |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2072-6694/15/13/3328 |
| _version_ | 1797592044572508160 |
|---|---|
| author | Elena Caproni Riccardo Corbellari Michele Tomasi Samine J. Isaac Silvia Tamburini Ilaria Zanella Martina Grigolato Assunta Gagliardi Mattia Benedet Chiara Baraldi Lorenzo Croia Gabriele Di Lascio Alvise Berti Silvia Valensin Erika Bellini Matteo Parri Alberto Grandi Guido Grandi |
| author_facet | Elena Caproni Riccardo Corbellari Michele Tomasi Samine J. Isaac Silvia Tamburini Ilaria Zanella Martina Grigolato Assunta Gagliardi Mattia Benedet Chiara Baraldi Lorenzo Croia Gabriele Di Lascio Alvise Berti Silvia Valensin Erika Bellini Matteo Parri Alberto Grandi Guido Grandi |
| author_sort | Elena Caproni |
| collection | DOAJ |
| description | In situ vaccination (ISV) is a promising cancer immunotherapy strategy that consists of the intratumoral administration of immunostimulatory molecules (adjuvants). The rationale is that tumor antigens are abundant at the tumor site, and therefore, to elicit an effective anti-tumor immune response, all that is needed is an adjuvant, which can turn the immunosuppressive environment into an immunologically active one. Bacterial outer membrane vesicles (OMVs) are potent adjuvants since they contain several microbe-associated molecular patterns (MAMPs) naturally present in the outer membrane and in the periplasmic space of Gram-negative bacteria. Therefore, they appear particularly indicted for ISV. In this work, we first show that the OMVs from <i>E. coli</i> BL21(DE3)Δ60 strain promote a strong anti-tumor activity when intratumorally injected into the tumors of three different mouse models. Tumor inhibition correlates with a rapid infiltration of DCs and NK cells. We also show that the addition of neo-epitopes to OMVs synergizes with the vesicle adjuvanticity, as judged by a two-tumor mouse model. Overall, our data support the use of the OMVs in ISV and indicate that ISV efficacy can benefit from the addition of properly selected tumor-specific neo-antigens. |
| first_indexed | 2024-03-11T01:45:53Z |
| format | Article |
| id | doaj.art-2acb1d1e5f1248ffb5ad00bf1871451c |
| institution | Directory Open Access Journal |
| issn | 2072-6694 |
| language | English |
| last_indexed | 2024-03-11T01:45:53Z |
| publishDate | 2023-06-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Cancers |
| spelling | doaj.art-2acb1d1e5f1248ffb5ad00bf1871451c2023-11-18T16:15:24ZengMDPI AGCancers2072-66942023-06-011513332810.3390/cancers15133328Anti-Tumor Efficacy of In Situ Vaccination Using Bacterial Outer Membrane VesiclesElena Caproni0Riccardo Corbellari1Michele Tomasi2Samine J. Isaac3Silvia Tamburini4Ilaria Zanella5Martina Grigolato6Assunta Gagliardi7Mattia Benedet8Chiara Baraldi9Lorenzo Croia10Gabriele Di Lascio11Alvise Berti12Silvia Valensin13Erika Bellini14Matteo Parri15Alberto Grandi16Guido Grandi17Toscana Life Sciences Foundation, Via Fiorentina 1, 53100 Siena, ItalyDepartment of Cellular, Computational and Integrative Biology (CIBIO), University of Trento, Via Sommarive 9, 38123 Trento, ItalyDepartment of Cellular, Computational and Integrative Biology (CIBIO), University of Trento, Via Sommarive 9, 38123 Trento, ItalyDepartment of Cellular, Computational and Integrative Biology (CIBIO), University of Trento, Via Sommarive 9, 38123 Trento, ItalyDepartment of Cellular, Computational and Integrative Biology (CIBIO), University of Trento, Via Sommarive 9, 38123 Trento, ItalyDepartment of Cellular, Computational and Integrative Biology (CIBIO), University of Trento, Via Sommarive 9, 38123 Trento, ItalyDepartment of Cellular, Computational and Integrative Biology (CIBIO), University of Trento, Via Sommarive 9, 38123 Trento, ItalyToscana Life Sciences Foundation, Via Fiorentina 1, 53100 Siena, ItalyToscana Life Sciences Foundation, Via Fiorentina 1, 53100 Siena, ItalyDepartment of Cellular, Computational and Integrative Biology (CIBIO), University of Trento, Via Sommarive 9, 38123 Trento, ItalyDepartment of Cellular, Computational and Integrative Biology (CIBIO), University of Trento, Via Sommarive 9, 38123 Trento, ItalyToscana Life Sciences Foundation, Via Fiorentina 1, 53100 Siena, ItalyDepartment of Cellular, Computational and Integrative Biology (CIBIO), University of Trento, Via Sommarive 9, 38123 Trento, ItalyToscana Life Sciences Foundation, Via Fiorentina 1, 53100 Siena, ItalyToscana Life Sciences Foundation, Via Fiorentina 1, 53100 Siena, ItalyDepartment of Experimental and Clinical Biomedical Sciences “Mario Serio”, University of Florence, Viale Morgagni 50, 50134 Florence, ItalyToscana Life Sciences Foundation, Via Fiorentina 1, 53100 Siena, ItalyDepartment of Cellular, Computational and Integrative Biology (CIBIO), University of Trento, Via Sommarive 9, 38123 Trento, ItalyIn situ vaccination (ISV) is a promising cancer immunotherapy strategy that consists of the intratumoral administration of immunostimulatory molecules (adjuvants). The rationale is that tumor antigens are abundant at the tumor site, and therefore, to elicit an effective anti-tumor immune response, all that is needed is an adjuvant, which can turn the immunosuppressive environment into an immunologically active one. Bacterial outer membrane vesicles (OMVs) are potent adjuvants since they contain several microbe-associated molecular patterns (MAMPs) naturally present in the outer membrane and in the periplasmic space of Gram-negative bacteria. Therefore, they appear particularly indicted for ISV. In this work, we first show that the OMVs from <i>E. coli</i> BL21(DE3)Δ60 strain promote a strong anti-tumor activity when intratumorally injected into the tumors of three different mouse models. Tumor inhibition correlates with a rapid infiltration of DCs and NK cells. We also show that the addition of neo-epitopes to OMVs synergizes with the vesicle adjuvanticity, as judged by a two-tumor mouse model. Overall, our data support the use of the OMVs in ISV and indicate that ISV efficacy can benefit from the addition of properly selected tumor-specific neo-antigens.https://www.mdpi.com/2072-6694/15/13/3328cancer vaccinesneo-epitopespersonalized medicineouter membrane vesicles (OMVs)adjuvants |
| spellingShingle | Elena Caproni Riccardo Corbellari Michele Tomasi Samine J. Isaac Silvia Tamburini Ilaria Zanella Martina Grigolato Assunta Gagliardi Mattia Benedet Chiara Baraldi Lorenzo Croia Gabriele Di Lascio Alvise Berti Silvia Valensin Erika Bellini Matteo Parri Alberto Grandi Guido Grandi Anti-Tumor Efficacy of In Situ Vaccination Using Bacterial Outer Membrane Vesicles Cancers cancer vaccines neo-epitopes personalized medicine outer membrane vesicles (OMVs) adjuvants |
| title | Anti-Tumor Efficacy of In Situ Vaccination Using Bacterial Outer Membrane Vesicles |
| title_full | Anti-Tumor Efficacy of In Situ Vaccination Using Bacterial Outer Membrane Vesicles |
| title_fullStr | Anti-Tumor Efficacy of In Situ Vaccination Using Bacterial Outer Membrane Vesicles |
| title_full_unstemmed | Anti-Tumor Efficacy of In Situ Vaccination Using Bacterial Outer Membrane Vesicles |
| title_short | Anti-Tumor Efficacy of In Situ Vaccination Using Bacterial Outer Membrane Vesicles |
| title_sort | anti tumor efficacy of in situ vaccination using bacterial outer membrane vesicles |
| topic | cancer vaccines neo-epitopes personalized medicine outer membrane vesicles (OMVs) adjuvants |
| url | https://www.mdpi.com/2072-6694/15/13/3328 |
| work_keys_str_mv | AT elenacaproni antitumorefficacyofinsituvaccinationusingbacterialoutermembranevesicles AT riccardocorbellari antitumorefficacyofinsituvaccinationusingbacterialoutermembranevesicles AT micheletomasi antitumorefficacyofinsituvaccinationusingbacterialoutermembranevesicles AT saminejisaac antitumorefficacyofinsituvaccinationusingbacterialoutermembranevesicles AT silviatamburini antitumorefficacyofinsituvaccinationusingbacterialoutermembranevesicles AT ilariazanella antitumorefficacyofinsituvaccinationusingbacterialoutermembranevesicles AT martinagrigolato antitumorefficacyofinsituvaccinationusingbacterialoutermembranevesicles AT assuntagagliardi antitumorefficacyofinsituvaccinationusingbacterialoutermembranevesicles AT mattiabenedet antitumorefficacyofinsituvaccinationusingbacterialoutermembranevesicles AT chiarabaraldi antitumorefficacyofinsituvaccinationusingbacterialoutermembranevesicles AT lorenzocroia antitumorefficacyofinsituvaccinationusingbacterialoutermembranevesicles AT gabrieledilascio antitumorefficacyofinsituvaccinationusingbacterialoutermembranevesicles AT alviseberti antitumorefficacyofinsituvaccinationusingbacterialoutermembranevesicles AT silviavalensin antitumorefficacyofinsituvaccinationusingbacterialoutermembranevesicles AT erikabellini antitumorefficacyofinsituvaccinationusingbacterialoutermembranevesicles AT matteoparri antitumorefficacyofinsituvaccinationusingbacterialoutermembranevesicles AT albertograndi antitumorefficacyofinsituvaccinationusingbacterialoutermembranevesicles AT guidograndi antitumorefficacyofinsituvaccinationusingbacterialoutermembranevesicles |